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The Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) blocks B-cell receptor (BCR) signal transduction in
EBV-immortalized B lymphocytes in vitro. The cytoplasmic amino-terminal domain of LMP2A contains an immunoreceptor
tyrosine activation motif (ITAM). ITAMs consist of paired tyrosine and leucine residues and play a central role in signal
transduction of the BCR and the T-cell receptor (TCR). To investigate the importance of the LMP2A ITAM, two EBV recombi-
nants were constructed, each containing a tyrosine-to-phenylalanine point mutation at amino acid 74 or 85 within the ITAM
of LMP2A. Tyrosine phosphorylation, calcium mobilization, and induction of BZLF1 expression were no longer blocked in
the LMP2A ITAM mutant LCLs following BCR cross-linking. In addition, the Syk protein tyrosine kinase (PTK) was unable
to bind LMP2A in unstimulated LCLs infected with either of the LMP2A ITAM mutants. Analysis of Syk phosphorylation
before and after BCR cross-linking in the LMP2A mutant ITAM LCLs compared with wild-type EBV LCLs indicates a specific
role of the LMP2A ITAM on the LMP2A-mediated negative effect on the Syk PTK. These data indicate the importance of
the LMP2A ITAM motif in the LMP2A-mediated block on BCR signal transduction and position the role of the Syk PTK as
being central to the function of LMP2A. q 1997 Academic Press
INTRODUCTION den, 1989; Kaye et al., 1993; Tomkinson et al., 1993; Far-
rell, 1995) and EBNA1 is likely essential for lymphocyte
Epstein–Barr virus (EBV) is a common human patho-
growth transformation, because it is required for EBV
gen that is the causative agent of mononucleosis. EBV
episome maintenance (Yates et al., 1985). However, EB-
also is associated with a variety of hemopoietic cancers
NA3B, LMP2A, and LMP2B are dispensible for lympho-such a African Burkitt’s lymphoma, Hodgkin’s disease,
cyte transformation (Longnecker et al., 1992, 1993a,adult T-cell leukemia, and lymphoproliferative diseases
1993b; Tomkinson and Kieff, 1992). Of the viral proteinsoccurring in individuals with congenital or acquired cellu-
expressed in latent infection, EBNA1, LMP1, and LMP2Alar immune deficiencies. Two epithelial diseases are also
are the proteins consistently detected in NPC tumorsassociated with EBV infection: nasopharyngeal carci-
biopsies, EBV-related malignancies, and lymphoprolifer-noma (NPC), a malignancy endemic to southern China;
ative diseases in AIDS patients [for review see Ambinderand oral hairy leukoplakia (OHL), an epithelial hyperpla-
and Mann (1994); Thorley-Lawson et al. (1996)]. In addi-sia of the lingual squamous epithelium in AIDS patients
tion, LMP2A and EBNA1 are the only messages of the[for review see Miller, (1990); Straus et al., (1993); Kieff,
in vitro latently expressed proteins that have been de-(1996)].
tected by PCR analysis from B lymphocytes purified fromB lymphocytes infected with EBV and grown in vitro are
individuals harboring EBV latent infections (Qu andimmortalized and are termed lymphoblastoid cell lines
Rowe, 1992; Tierney et al., 1994; Chen et al., 1995). Thus,(LCLs). These EBV-transformed LCLs contain EBV epi-
EBNA1, LMP1, and LMP2A may have important roles insomes and nine virus-encoded proteins. Six are nuclear
vivo for viral replication, persistence, and EBV-relatedproteins: EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C,
diseases in the human host.and EBNALP [for review see Kieff (1996)], and three are
The LMP2A protein, the subject of this study, localizesintegral membrane proteins: LMP1 (Mann et al., 1985;
to numerous small patches in the plasma membrane ofWang et al., 1985), LMP2A, and LMP2B (Frech et al.,
latently infected B lymphocytes (Longnecker and Kieff,1990; Longnecker and Kieff, 1990; Rowe et al., 1990).
1990; Longnecker et al., 1991) and most of the anti-phos-EBNA2, EBNA3A, EBNA3C, and LMP1 have been demon-
photyrosine (APT) reactivity within these B cells is associ-strated to be essential for EBV transformation of B lym-
ated with these LMP2A patches (Longnecker et al., 1991).phocytes (Cohen et al., 1989; Hammerschmidt and Sug-
Within the 119-amino-acid amino-terminal domain of
LMP2A are 8 tyrosine residues, 2 of which form an immu-
1 To whom correspondence and reprint requests should be ad- noreceptor tyrosine-based activation motif (ITAM) (Fig.dressed at Department of Microbiology–Immunology, Northwestern
1A) (Reth, 1989; Cambier, 1995). Antigen-induced B-lym-University Medical School, 303 East Chicago Avenue, Chicago, IL
60611. Fax: (312) 503-1339. E-mail: r-longnecker@nwu.edu. phocyte proliferation and differentiation result from the
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phosphorylated LMP2A might mimic activated receptor
complexes, thereby competing for proteins with src ho-
mology 2 domains (SH2). SH2 domains are noncatalytic
domains conserved among cytoplasmic signaling pro-
teins which bind tyrosine phosphorylated proteins [for
review, see Pawson and Gish (1992); Schaffhausen
(1995)].
Prior results with three deletion mutations within the
amino-terminal domain of LMP2A indicated the potential
importance of the LMP2A ITAM (Fruehling et al., 1996),
although these studies were hindered by potential arti-
facts that can be obtained by deletional mutagenesis.
Thus, to further investigate the importance of the LMP2A
ITAM in a site-specific approach, two separate point mu-
tations were engineered into each of the tyrosine resi-
dues of the LMP2A ITAM. Each tyrosine was changed
to a phenylalanine residue and these mutations were
recombined into the EBV genome. LCLs infected with
each LMP2A ITAM mutation, as well as wild-type con-
trols, were tested for Syk association with LMP2A,FIG. 1. Predicted structure of LMP2A and binding of Syk PTK to
LMP2A effects on the Syk PTK, calcium mobilization, tyro-LMP2A amino acids Y74 and Y85. (A) Amino acid sequence comparison
of the immunoreceptor tyrosine-based activation motifs (ITAM) of the sine phosphorylation, and activation of BZLF1 expression
Ig-a, Ig-b, and LMP2A proteins. The tyrosine residues of the LMP2A following BCR cross-linking.
ITAM are amino acids 74 and 85 of LMP2A. (B) A schematic representa-
tion of the LMP2A protein illustrating the 119-amino-acid cytoplasmic
amino-terminal domain, the 12 transmembrane domains, and the 27- MATERIALS AND METHODS
amino-acid cytoplasmic carboxyl domain. The eight tyrosine residues
in the LMP2A amino-terminal domain are numbered and the binding Cell lines and cell culture
of the two SH2 domains of the Syk PTK with LMP2A at tyrosine residues
Y74 and Y85 is depicted. Tyrosine residues 74 and 85 of the LMP2A All cell lines were maintained in RPMI containing 10%
ITAM were changed independently to a phenylalanine residue and
inactivated fetal bovine serum, 1000 units/ml of penicillin,recombined into the EBV genome to generate LCLs containing each
and 1000 mg/ml of streptomycin (Sigma). BJAB is an EBV-LMP2A ITAM mutation.
negative B-lymphoma cell line (Menezes et al., 1975). The
HH514-16 subclone of the original EBV-infected P3HR1
(P3JHR1) Burkitt’s lymphoma cell line (a gift of Georgesequential activation of the Syk PTK and the Src family
PTKs and their interaction with phosphorylated ITAMs Miller) has only EBV genomes with a single type of DNA
that is deleted for a segment encoding EBNA2 and the[for review see Bolen, (1993); Cambier et al. (1994); Weiss
and Littman (1994); DeFranco (1995); Gold and Matsuu- last two exons of EBNALP (Heston et al., 1982). WT1 and
WT4 are EBV/LMP2A/ lymphoblastoid cell lines (LCLs)chi (1995)]. The Src family PTKs and the Syk PTK also
associate with LMP2A (Longnecker et al., 1991; Burk- and ES1 and ES4 are EBV/LMP2A0 LCLs (Miller et al.,
1994). Primary human mononuclear cells were obtainedhardt et al., 1992; Miller et al., 1995), and LMP2A induces
the phosphorylation of Syk in vivo or in in vitro kinase from blood of healthy donors by centrifugation over a
cushion of Ficoll-Paque (Pharmacia). For EBV-positivereactions (Longnecker et al., 1991; Burkhardt et al., 1992;
Miller et al., 1995). Transfection studies of LMP2A cDNA donors, T lymphocytes were removed as previously de-
scribed (Marchini et al., 1991).mutant constructs into an EBV0 B-lymphoma cell line
have revealed that the amino-terminal 119-amino-acid
domain of LMP2A is required for interaction with Syk and Construction of plasmids
the Src family PTKs. (Longnecker et al., 1991; Burkhardt
et al., 1992). pSVNaeZ, used to induce lytic EBV replication and
EcoRI-A, used to rescue the EBNA2 and EBNALP muta-EBV/LMP2A/ LCLs are blocked in BCR-stimulated cal-
cium mobilization, tyrosine phosphorylation, and lytic ac- tions contained in the P3HR1 cell line, have been de-
scribed previously (Marchini et al., 1991; Swaminathantivation compared with EBV/LMP2A0 LCLs (Miller et al.,
1993, 1994, 1995). The 119-amino-acid cytoplasmic et al., 1991). Tyrosine residues 74 and 85 of LMP2A were
mutated to phenylalanine residues (Fig. 1) using a PCR-amino-terminal domain of LMP2A is essential for this
function of LMP2 (Burkhardt et al., 1992; Miller et al., based strategy. Genomic mutations were incorporated
into pRH6 which contains a KpnI (B95-8, bp 161,097)-to-1994). LMP2A functions as a negative regulator of the
Src family PTK, Lyn, and the Syk PTK (Miller et al., 1995). EcoRI (B95-8, bp 1) fragment from B95-8 EBV DNA. All
mutants were sequenced to confirm the presence of theConstitutively clustered membrane patches of tyrosine
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desired mutation and the absence of any mutations intro- tion. Ethidium bromide-stained PCR products were
viewed after electrophoresis through 1.5% EEO agaroseduced by PCR.
(Fisher) to identify the size of the amplified products.
Transfection Identified LMP2A ITAM mutant LCLs and wild-type con-
trols were further characterized for sIg expression byDNA used for transfections was banded twice on CsCl
flow cytometry utilizing a fluorescein isothiocyanate-density gradients. Recombinant cell lines were gener-
linked goat anti-human Ig (H / L) diluted 1:50 (Southernated by transfecting 1 1 107 P3HR1 cells in 0.4 ml com-
Biotech) as previously described (Miller et al., 1993).plete RPMI with 15 mg pSVNaeZ, 7 mg EcoRI-A, and 25
mg recombinant LMP2A DNA. Cells were pulsed once
Immunofluorescencewith a Gene Pulser (Bio-Rad) at 200 V and 960-mF capaci-
tance in a 0.4-cm electrode gap cuvette (Bio-Rad) and Immunofluorescence of LCLs was performed as pre-
immediately diluted in 10 ml complete RPMI. The induc- viously described (Longnecker and Kieff, 1990). In brief,
tion of lytic EBV replication in LCLs was performed simi- LCLs were fixed to glass slides with acetone at 0207 for
larly, except these cells were pulsed at 230 V with 25 mg 5 min, blocked with 20% normal goat serum for 10 min
pSVNaeZ and diluted in complete RPMI containing 20 at room temperature, incubated with the anti-LMP2A rat
ng of 12-O-tetradecanolylphorbol-13-acetate (TPA) per monoclonal antibody (Fruehling et al., 1996), 14B7, di-
milliliter. luted 1:1000 for 1 hr at room temperature, incubated with
a goat anti-rat-Cy3 secondary antibody diluted 1:1000
Mutation of the LMP2A ITAM
(Jackson) for 30 min, washed in PBS, and viewed with a
Zeiss fluorescence Axioscope.PCR-mediated mutagenesis was used to create EBV
DNA fragments encoding LMP2A with point mutations
in the LMP2A ITAM. Both of the recombinant LMP2A Immunoblotting
constructs were verified by sequencing and then incor-
LMP2A. LCLs (5 1 106) were washed twice in PBS,porated into virus through a strategy utilizing the transfor-
lysed in 1% NP-40 lysis buffer [1% Nonidet-P40, 50 mMmation-incompetent, replication-competent EBV deletion
Tris–HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 10 mgmutant, P3HR1. Recombinant virus was generated by the
(each) pepstatin and leupeptin per milliliter, 0.5 mM phe-cotransfection of the P3HR1 cell line with pSVNaeZ DNA,
nylmethylsulfonyl fluoride, 1 mM sodium orthovanadate],to induce lytic viral replication; EcoRI-A DNA, to rescue
and centrifuged at 47 to remove the insoluble materials.the EBNA2 and EBNALP deletions in the P3HR1 genome;
Lysates were heated at 707 for 5 min, separated by SDS–and each of the recombinant LMP2A DNA fragments
8% PAGE, transferred to nitrocellulose, blocked with 4%(Longnecker et al., 1992). The recombinant P3HR1 vi-
milk for 1 hr at room temperature, probed with the anti-ruses were used to infect primary blood mononuclear
LMP2A 8C3 rat monoclonal antibody for 1 hr at roomcells (PBMCs) or purified B lymphocytes in culture as
temperature, incubated with horseradish peroxidase-previously described (Fruehling et al., 1996). Clones
linked anti-rat secondary antibody for 30 min at roomemerged 3 to 5 weeks after initial plating and were
temperature (Amersham), washed with Tris-buffered sa-screened by PCR for incorporation of the LMP2A ITAM
line–Tween (TBST), and detected by enhanced chemilu-point mutations at 6 to 8 weeks.
minescence (ECL) (Pierce).
BZLF1. LCLs (4 1 106 cells) were either treated withPCR analysis and identification of LMP2A ITAM
100 mg/ml goat anti-human Ig F(ab*)2 (Jackson) or leftmutant LCLs
untreated for 48 hr at 377. After incubation, cells were
Genomic DNA from LCLs was prepared (Swaminathan washed in PBS and whole cell lysates were separated by
et al., 1991) and amplified in a 25-ml volume for 40 cycles electrophoresis through SDS–8% PAGE. Proteins were
as previously described (Longnecker et al., 1992). transferred to nitrocellulose, blocked in 5% milk, incu-
Primers 5*LMP1 (CTAGGCGCACCTGGAGGTGG) and bated with BZ1 monoclonal antibody to the BZLF1 protein
3*LMP1 (AGTCAGTCAGGCAAGCCTAT) were used to (Young et al., 1991) for 1 hr at room temperature, incu-
screen LCLs containing the 81-bp smaller LMP1 gene bated with a secondary anti-mouse-HRP antibody (Amer-
present in the EBV genomic DNA fragment in which the sham), washed in TBST, and detected by ECL (Pierce).
LMP2A mutations were incorporated. The LMP1 gene is
adjacent to the LMP2A gene within the EBV genome. Cellular activation and preparation of lysates
After this initial screen, primers 5*LMP2A (CTGCTGCAG-
CTATGGGGTCC) and 3*74-LMP2A (TTGGGTTCCTAG- Tissue culture cells (cell number indicated in figure
legends) were resuspended and equilibrated in serum-TGGTTGAA) were used to specifically amplify DNA from
LCLs incorporating the LMP2AY74 ITAM point mutation, free RPMI for 15 min at 377. Cells were stimulated with
25 mg/ml goat anti-human Ig (Southern Biotech) for thewhile primers 5*LMP2A and 3*85-LMP2A (GTCGTGTTG-
CAATCCCAAGA) were used to specifically amplify DNA indicated times and cells were immediately lysed in 1%
NP-40 lysis buffer. The insoluble materials were removedfrom LCLs incorporating the LMP2AY85 ITAM point muta-
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by centrifugation at 47 and cleared supernatants were (Fig. 1B). Both of the recombinant LMP2A constructs
were verified by sequencing (data not shown) and thenprocessed for immunoprecipitations.
incorporated into the EBV viral genome through a pre-
Immunoprecipitations and immunoblotting viously described strategy (Longnecker et al., 1992). The
recombinant viruses generated were used to infect pri-Cleared lysates were incubated with the appropriate
mary blood mononuclear cells (PBMCs) or purified B lym-antisera for 1 hr at 47, and immune complexes were
phocytes in culture to generate LCLs as previously de-captured with either Protein A or G–Sepharose (Phar-
scribed (Fruehling et al., 1996). The generated LCLs weremacia) for 1 hr as indicated in the figure legends, fol-
screened by PCR to identify the presence of the LMP2Alowed by four washes with 1% NP-40 lysis buffer. Immu-
ITAM mutations within the infecting EBV genome (datanoprecipitated proteins were then resuspended in 21
not shown). Multiple cell lines were transformed by eachSDS sample buffer, heated at 707 for 5 min, and sepa-
of the LMP2A ITAM recombinant viruses and theserated by electrophoresis through SDS–polyacrylamide
EBV/LMP2AY74 and EBV/LMP2AY85 LCLs are charac-gels (percentages are indicated in the figure legends).
terized in this study.For immunoblotting, immune complex materials were
electrophoresed and transferred to either nitrocellulose
LMP2A protein expression in EBV/LMP2A ITAM
or immobilon, as indicated in the figure legends. Mem-
mutant LCLs
branes were blocked for 1 hr at room temperature and
then incubated in primary antibody, diluted in TBST, for 1 Expression of LMP2A in EBV/LMP2AY74 and
hr at room temperature. Membranes were washed three EBV/LMP2AY85 LCLs was confirmed in immunoblots
times in TBST, incubated with a horseradish-peroxidase- using the LMP2A-specific antibody 8C3. Representa-
linked secondary antibody (Amersham) for 30 min at tive data are shown in Fig. 2. LMP2A expression in
room temperature, washed four times in TBST, and de- four EBV/LMP2A/ LCLs was clearly evident (Fig. 2,
tected by ECL (Pierce). Mouse monoclonal antibodies to lanes 3 – 6), while no LMP2A was detected in the nega-
Syk (4D10) and phosphotyrosine (PY20 and PY20-HRP) tive control EBV/LMP2A0 LCL ES1 (Fig. 2, lane 2) or
used in immunoprecipitations and immunoblots were the EBV0 cell line BJAB (Fig. 2, lane 1). LMP2A expres-
purchased from Santa Cruz. sion in four representative EBV/LMP2AY74 LCLs (Fig.
2, lanes 7 – 10) and four representative EBV/LMP2AY85
Calcium mobilization LCLs (Fig. 2, lanes 11 – 14) was similar to the LMP2A
expression in EBV/LMP2A/ LCLs. Immunofluores-Tissue culture cells (3 1 106 cells) were resuspended
cence microscopy utilizing anti-LMP2A antibodies veri-in loading buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl2 ,
fied that the LMP2A subcellular protein localization1 mM CaCl2 , 10 mM glucose, 10 mM HEPES, 1% BSA,
within the EBV/LMP2AY74 and EBV/LMP2AY85 LCLsand 2.5 mM probenicid) and loaded with 2 mM calcium-
was similar to LMP2A subcellular localization inbinding dye, fluo-3-acetoxymethyl ester (fluo-3) for 30 min
EBV/LMP2A/ LCLs (data not shown) as previously de-at room temperature (Molecular Probes). After loading,
scribed (Fruehling et al., 1996).the cells were washed twice and resuspended in loading
buffer. The prepared cells were then measured for fluo-
Syk PTK binding to the LMP2A ITAMrescence after BCR cross-linking with goat anti-human
Ig F(ab*)2 antibody (Jackson) in a Perkin–Elmer LS-5B In order to evaluate the specific interaction of Syk with
luminescence spectrometer. Excitation and emission val- the LMP2A ITAM, unstimulated cellular lysates from
ues for fluo-3 are 505 and 530 nm, respectively. Autofluor- EBV/LMP2AY74, EBV/LMP2AY85, and EBV/LMP2A/
escence (or Fmin) for each LCL was also determined by LCLs were tested in parallel immunoprecipitations with
performing the above procedure without adding fluo-3 either LMP2A-specific antibodies or Syk-specific anti-
dye. Baseline fluorescence was recorded for 1 min and bodies (Fig. 3). LMP2A was immunoprecipitated from
maximal fluorescence (Fmax) was measured by addition EBV/LMP2AY74, EBV/LMP2AY85, and EBV/LMP2A/
of digitonin (40 mM). Calcium concentration (nM) was LCLs and immunoblotted with a LMP2A-specific antibody
calculated according to the formula [Ca2/]  400 (F 0 to verify equal levels of immunoprecipitated LMP2A in
Fmin)/(Fmax 0 F) (Merrit et al., 1990; Lee and Stern, 1994). each of the LCLs (Fig. 3A). LMP2A was not detected in
an EBV/LMP2A0 LCL included as a negative control (Fig.
RESULTS 3A). To test for Syk interaction with LMP2A, Syk was
immunoprecipitated from the same cellular lysates andMutation of the LMP2A ITAM
immunoblotted with either Syk-specific antibodies (Fig.
3B), to confirm equal amounts of immunoprecipitatedPCR-mediated mutagenesis was used to create EBV
DNA fragments encoding LMP2A with point mutations in Syk, or LMP2A-specific antibodies, to investigate the in-
teraction of Syk with LMP2A (Fig. 3C). Syk was readilythe LMP2A ITAM. Each of the LMP2A tyrosine residues
74 (Y74) and 85 (Y85) within the amino-terminal domain immunoprecipitated from each of the LCLs, but the
coimmunoprecipitation of LMP2A was detected only inof LMP2A was changed to a phenylalanine (F) residue
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FIG. 2. LMP2A expression in EBV/LMP2A/ and ITAM mutant LCLs. LMP2A expression levels were analyzed in four EBV/LMP2A/ LCLs (lanes
3 to 6), four EBV/LMP2AY74 LCLs (lanes 7 to 10), and four EBV/LMP2AY85 LCLs (lanes 11 to 14). No LMP2A expression was detected in the EBV0
cell line BJAB (lane 1) or the EBV/LMP2A0 LCL ES1 (lane 2). NP40 lysates of 1 1 107 LCLs were separated by SDS–8% PAGE, transferred to
nitrocellulose, probed with the anti-LMP2A 8C3 antibody, incubated with horseradish peroxidase-linked secondary antibody, washed, and detected
by ECL. LCL clone numbers are indicated above each lane and protein standards are indicated in kilodaltons.
the EBV/LMP2A/ LCL and not in EBV/LMP2A0, missing either of the conserved tyrosine residues of the
LMP2A ITAM, are unable to bind Syk. Hence, it appearsEBV/LMP2AY74, or EBV/LMP2AY85 LCLs. These data
demonstrate that unlike wild-type EBV/LMP2A/ LCLs, that both tyrosine residues of the LMP2A ITAM are re-
quired for the interaction of LMP2A with Syk.the mutant EBV/LMP2AY74 and EBV/LMP2AY85 LCLs,
Mutation of the LMP2A ITAM restores BCR-activated
tyrosine phosphorylation
To investigate the effect of the LMP2A ITAM muta-
tions on the induction of PTK activity, one of the earliest
known biochemical effects after BCR cross-linking,
EBV/LMP2A/, EBV/LMP2AY74, and EBV/LMP2AY85
LCLs, matched for sIg expression by flow cytometry
(data not shown), were analyzed for induction of tyro-
sine phosphorylation following BCR cross-linking. Rep-
resentative data are shown in two immunoblots. The
induction of tyrosine phosphorylation in two represen-
tative EBV/LMP2A/ LCLs and two representative
EBV/LMP2AY74 LCLs is shown in Fig. 4A and the in-
duction of tyrosine phosphorylation for two representa-
tive EBV/LMP2A/ LCLs and two representative
EBV/LMP2AY85 LCLs is shown in Fig. 4B. In the four
EBV/LMP2A/ LCLs, a number of proteins are constitu-
tively phosphorylated in unstimulated LCLs (Figs. 4A
and 4B, lanes 1 and 4) and this pattern remains rela-
tively unchanged after sIg cross-linking (Figs. 4A and
4B, lanes 2 and 3 and lanes 5 and 6). As described
FIG. 3. LMP2A coimmunoprecipitates with the Syk PTK in
earlier, LMP2A was the dominant phosphorylated pro-EBV/LMP2A/ LCLs but not in LMP2A ITAM mutant LCLs. (A) Expres-
tein in EBV/LMP2A/ LCLs and its level of phosphoryla-sion of LMP2A is detected in an EBV/LMP2A/ LCL (A, lane 1), an
EBV/LMP2AY74 LCL (A, lane 3), and an EBV/LMP2AY85 LCL (A, lane tion did not change over time (Figs. 4A and 4B, lanes 1 –
4), while no LMP2A was detected in an EBV/LMP2A0 LCL (A, lane 2). 3 and 4 – 6, arrow). This 54-kDa phosphorylated protein
(B) Equivalent levels of the Syk PTK are immunoprecipitated from all was confirmed to be LMP2A by stripping the blot and
four of the LCLs: EBV/LMP2A/ LCL (B, lane 1), EBV/LMP2A0 LCL (B,
reprobing it with the LMP2A-specific antibody 8C3lane 2), EBV/LMP2AY74 LCL (B, lane 3), and EBV/LMP2AY85 LCL (B,
(data not shown). In contrast, there was little constitu-lane 4). (C) LMP2A coimmunoprecipitates with Syk in an EBV/LMP2A/
LCL (C, lane 1), but not in an EBV/LMP2A0 LCL (C, lane 2), an tive phosphorylation in untreated cellular lysates from
EBV/LMP2AY74 LCL (C, lane 3), and an EBV/LMP2AY85 LCL (C, lane EBV/LMP2AY74 and EBV/LMP2AY85 LCLs (Figs. 4A
4). Unstimulated LCLs (11 106 cells/ip) were lysed and immunoprecipi- and 4B, lane 7), but upon BCR cross-linking there was
tated in parallel with anti-LMP2A or anti-Syk antibodies. Following im-
a dramatic increase in the number of proteins whichmunoprecipitation, proteins were separated by SDS–6% PAGE and
were tyrosine phosphorylated (Figs. 4A and 4B, lanestransferred to immobilon. The LMP2A immunoprecipitation was immu-
noblotted with the anti-LMP2A rat monoclonal antibody, 14B7 (A), while 7 – 9 and 10 – 12). This increase in tyrosine phosphory-
the Syk immunoprecipitation was divided equally to generate two im- lated proteins following BCR cross-linking was similar
munoblots which were probed with either the anti-Syk murine mono- to that observed in EBV/LMP2A0 LCLs or in a EBV0 B
clonal antibody, 4D10, (B) or the anti-LMP2A 14B7 antibody (C). Each
lymphoma cell line as previously described (Miller etimmunoblot was then incubated with an HRP-conjugated secondary
al., 1995). Like EBV/LMP2A/ LCLs, LMP2A in theantibody and detected by ECL. LCL clone numbers are indicated above
each lane and protein standards are indicated in kilodaltons. EBV/LMP2AY74 and EBV/LMP2AY85 LCLs was con-
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FIG. 4. Protein tyrosine phosphorylation following BCR cross-linking in EBV/LMP2A/ and LMP2A ITAM mutant LCLs. (A and B) The tyrosine phosphoryla-
tion pattern of four EBV/LMP2A/ LCLs (A and B, lanes 1–6), two EBV/LMP2AY74 LCLs (A, lanes 7–12), and two EBV/LMP2AY85 LCLs (B, lanes 7–12)
are depicted before (0) and after (1 and 5 min) BCR cross-linking. LCLs (2 1 107 cells/ml) were either untreated (0) or treated with anti-sIg antibody for
the indicated times and lysed in 1% NP-40 lysis buffer. Cleared lysates were immunoprecipitated with the PY20 APT antibody, captured with protein A–
Sepharose beads, separated by SDS–8% PAGE, transferred to nitrocellulose, immunoblotted with the horseradish peroxidase-coupled PY20 antibody,
and detected by ECL. LCL clone numbers are indicated above each group of lanes and protein standards are indicated in kilodaltons.
stitutively phosphorylated and the phosphorylation ylation before and after BCR cross-linking were in-
state of LMP2A remained constistent at all time points vestigated in EBV/LMP2A/, EBV/LMP2AY74, and
following BCR cross-linking, although the level of EBV/LMP2AY85 LCLs. The level of Syk within each LCL
LMP2A phosphorylation within the ITAM mutant LCLs was determined using a Syk-specific antibody in immu-
was reduced compared with EBV/LMP2A/ LCLs. noprecipitation followed by a Syk immunoblot (Figs. 5A
and 5C). Syk protein expression was similar in all cells,
Syk is phosphorylated following BCR cross-linking in both wild-type and mutant. However, in studies using the
the LMP2A ITAM mutant LCLs in contrast to same Syk immunoprecipitation followed by an antiphos-
EBV/LMP2A/ LCLs photyrosine (APT) immunoblot, induction of Syk phos-
phorylation was observed following BCR cross-linking inTo investigate the effect of the LMP2A ITAM mutations
on Syk phosphorylation, Syk protein levels and phosphor- the LMP2A ITAM mutant LCLs. Within four representative
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(data not shown), were loaded with the calcium-binding
dye fluo-3 and monitored for fluorescence after BCR
cross-linking. Previously described EBV/LMP2A/ (Table
1, WT1 and WT4) and EBV/LMP2A0 (Table 1, ES1 and
ES2) LCLs were included as controls (Miller et al., 1994).
EBV/LMP2A/ LCLs demonstrated a minimal calcium flux
after BCR cross-linking (Table 1, 8–40%). These calcium
flux values appear negligible when compared to the cal-
cium flux values of the EBV/LMP2A0 LCLs (Table 1,
compare 8–40% with 231–244%). Representative
EBV/LMP2A ITAM point mutant LCLs were also tested
and had an observed mean calcium flux of 95–191% (Y74
mutants) and 76–228% (Y85 mutants), a mean greater
than EBV/LMP2A/ LCLs (Table 1, 8–40%). These data
TABLE 1
Calcium Mobilization in EBV/LMP2A/, EBV/LMP2A0, and LMP2A
ITAM Mutant LCLs after BCR Cross-linkinga
FIG. 5. Syk expression and phosphorylation in EBV/LMP2A/ and
% Calcium
LMP2A ITAM mutant LCLs following BCR stimulation. (A and C) The
Cell line type and nameb No.c increased
level of immunoprecipitated Syk protein (A and C) is consistent before
(0) and after (1 and 5 min) BCR cross-linking in four EBV/LMP2A/
EBV/LMP2A/ LCLs
LCLs (A and C, lanes 1–6), two EBV/LMP2AY74 LCLs (A, lanes 7–9)
WT1 7 8% (0–21%)
and two EBV/LMP2AY85 LCLs (C, lanes 10–12). (B and D) Syk is
WT4 11 13% (0–31%)
constitutively phosphorylated prior to BCR cross-linking and there is
no induction of phosphorylation of Syk following BCR cross-linking in WT.1.1 3 40% (0–65%)
four EBV/LMP2A/ LCLs (B and D, lanes 1–6). Syk is not constitutively WT.1.7 3 26% (12–51%)
phosphorylated in two EBV/LMP2AY74 LCLs (B, lanes 7–9) and two WT.8 4 23% (9–38%)
EBV/LMP2AY85 LCLs (D, lanes 10–12) but Syk phosphorylation is WT.11 3 24% (15–30%)
induced following BCR cross-linking within 1 min after BCR cross- WT.6 3 14% (10–17%)
linking. LCLs (2 1 106 cells/ip) were treated with anti-sIg, lysates were WT.7 3 17% (15–19%)
prepared, and anti-Syk immunoprecipitations followed by parallel Syk WT.23 3 18% (9–23%)
or APT immunoblots were performed as indicated. Proteins were sepa- EBV/LMP2A0 LCLs
rated by duplicate SDS–8% PAGE, transferred to nitrocellulose, immu- ES1 5 244% (131–423%)
noblotted with either the HRP-conjugated PY20 antibody or 4D10 anti- ES4 13 231% (131–345%)
body followed by a HRP-conjugated protein A, and detected by ECL. EBV/LMP2AY74 and EBV/LMP2AY85
LCL clone numbers are indicated above each group of lanes and pro- ITAM mutant LCLs
tein standards are indicated in kilodaltons. LMP2AY74.31 2 161% (92–231%)
LMP2AY74.7 4 126% (101–170%)
LMP2AY74.11 3 191% (151–229%)
LMP2AY74.36 2 95% (94–96%)EBV/LMP2A/ LCLs, Syk remained constitutively phos-
LMP2AY74.41 2 134% (67–200%)phorylated after BCR crosslinking (Fig. 5D, lanes 1–3 and
4–6). However, in two representative EBV/LMP2AY74 LMP2AY85.18 5 228% (70–314%)
LMP2AY85.A.2 2 119% (49–129%)LMP2A LCLs (Fig. 5B, lanes 7–9 and 10–12) and two
LMP2AY85.F.3 2 76% (25–92%)representative EBV/LMP2AY85 LMP2A LCLs (Fig. 5D,
lanes 7–9 and 10–12) Syk was not phosphorylated be- a LCLs (3 1 106 cells) were loaded with fluo-3-acetoxymethyl ester
fore BCR cross-linking, but was rapidly phosphorylated in calcium binding dye or left untreated and measured for fluorescence (F)
an inducible fashion following BCR cross-linking. These after BCR cross-linking in a luminescence spectrometer. The untreated
cells revealed an autofluorescence value (Fmin) for each LCL and theresults indicate that each tyrosine residue of the LMP2A
addition of digitonin to each cell sample gave a maximum fluorescenceITAM plays a critical role in the LMP2A-mediated inhibi-
value (Fmax) for each LCL. These values were then used to determinetion of Syk activation. calcium mobilization by determining the calcium concentration, ac-
cording to the formula [Ca2/]  400(F 0 Fmin)/(Fmax 0 F) (Merrit et al.,
1990; Lee and Stern, 1994).Calcium mobilization in EBV/LMP2A/ and
b WT1, WT4, ES1, and ES4 were previously described LCLs (MillerEBV/LMP2A ITAM mutant LCLs following
et al., 1994). All other LCLs were derived in this study.BCR cross-linking c Number of times calcium mobilization was determined for each
LCL.To assess the effect of the LMP2A ITAM mutations d The mean percentage increase of calcium was calculated for each
on calcium mobilization, multiple EBV/LMP2A/, EBV/- LDL. Values in parentheses indicate the range of calcium values deter-
LMP2AY74, and EBV/LMP2AY85 LCLs, derived in paral- mined for each LCL that were used to calculate the mean percentage
calcium increase.lel and matched for BCR expression by flow cytometry
AID VY 8690 / 6a3f$$$381 07-31-97 08:18:53 viral AP: VY
248 FRUEHLING AND LONGNECKER
DISCUSSION
In this study, each tyrosine of the LMP2A ITAM was
demonstrated to be essential for the constitutive block
in the BCR signal transduction cascade observed in EBV-
transformed B lymphocytes. This motif plays an important
role in the communication between the BCR and the Src
family PTKs (Lyn, Blk, Fyn, and Lck) and the Syk PTK [for
review see Bolen, (1993); Cambier et al. (1994); Weiss
and Littman (1994); DeFranco (1995); Gold and Matsuu-
FIG. 6. Induction of BZLF1 expression following BCR cross-linking chi (1995)]. The importance of the LMP2A ITAM, which
in the LMP2A ITAM mutant LCLs but not in EBV/LMP2A/ LCLs. The
includes tyrosine 74 and tyrosine 85 of the LMP2A aminoinduction of BZLF1 expression is detected in LMP2A ITAM mutant LCLs
acid sequence, is suggested by the conservation of thisupon BCR cross-linking (compare lanes 1 and 2, lanes 3 and 4, lanes
5 and 6, and lanes 7 and 8). No induction of BZLF1 expression is region within EBV clinical isolates sequenced to date
observed in EBV/LMP2A/ LCLs (compare lanes 9 and 10 and lanes (Busson et al., 1995). The LMP2A ITAM is also conserved
11 and 12). Whole-cell lysates of each LCL (0 or / BCR cross-linking) in the LMP2A homologue in herpesvirus papio, a B-
were separated by SDS–8% PAGE, transferred to nitrocellulose, probed
lymphotropic herpesvirus which naturally infects ba-with BZ1 monoclonal antibody, incubated with a secondary anti-mouse-
boons (Franken et al., 1995).HRP antibody, and detected by ECL. LCL clone numbers are indicated
above each pair of lanes and protein standards are indicated in kilodal- In this study, two EBV recombinant viruses were con-
tons. structed that encode a tyrosine-to-phenylalanine point
mutation at LMP2A residue Y74 or Y85. LCLs were
derived and analyzed for each mutant virus. Cross-
demonstrate that both LMP2A ITAM tyrosine point mu- linking the BCR on the ITAM mutant LCLs results in
tant LCLs readily mobilize calcium following BCR cross- a BCR signal transduction cascade characteristic of
linking, unlike EBV/LMP2A/ LCLs which demonstrate a normal B lymphocytes, EBV0 B-lymphoma cell lines, or
block in BCR cross-linking-induced calcium mobilization. EBV/LMP2A0 LCLs as determined by the induction of
tyrosine phosphorylation, activation of the Syk PTK,
Induction of BZLF1 expression in EBV/LMP2A ITAM
release of intracellular calcium, and nuclear gene
mutant LCLs following BCR cross-linking
transcription as measured by activation of BZLF1 ex-
pression, whereas these events do not occur inIn this study, the activation of lytic replication was in-
EBV/LMP2A/ LCLs (Burkhardt et al., 1992; Miller etvestigated in EBV/LMP2A/, EBV/LMP2AY74, and
al., 1993, 1994, 1995; Fruehling et al., 1996). MutatingEBV/LMP2AY85 LCLs following BCR cross-linking by an-
either of the LMP2A ITAM tyrosine residues also re-alyzing the expression of BZLF1, the immediate-early
sults in loss of constitutive phosphorylation and bind-transactivator of EBV lytic replication. The BCR was
ing of the Syk PTK to LMP2A.either untreated or cross-linked in representative
Consistent with the data presented in this study is theEBV/LMP2AY74, EBV/LMP2AY85, or EBV/LMP2A/
following model for the LMP2A-mediated block of signalLCLs for 48 hr and monitored for BCR-induced expres-
transduction within latently infected B lymphocytes. Insion of BZLF1 by immunoblots with the BZ1 monoclonal
this model, LMP2A constitutively aggregates in theantibody (Young et al., 1991; Miller et al., 1994). BZLF1
plasma membrane of EBV-infected LCLs resemblingexpression is evident after BCR cross-linking in the two
cross-linked BCRs. Like cross-linked BCRs, LMP2A re-representative EBV/LMP2AY74 LCLs (Fig. 6, lanes 2 and
cruits cellular PTKs, resulting in the phosphorylation of4) and the two representative EBV/LMP2AY85 LCLs (Fig.
the tyrosines within the LMP2A cytoplasmic amino-termi-6, lanes 6 and 8). Whereas no BZLF1 expression is de-
nal domain. In addition, LMP2A may also recruit SH3-tected in any of the point mutants before BCR cross-
containing proteins or proteins with WW domains (Chenlinking (Fig. 6, lanes 1, 3, 5, and 7) or in the EBV/LMP2A/
and Sudol, 1995; Sudol et al., 1995) to its proline-richLCL 1.1 either before or after BCR cross-linking (Fig. 6,
regions either before or after phosphorylation of thelanes 11 and 12). The EBV/LMP2A/ LCL 6 had a small
LMP2A tyrosines. In particular, the ITAM of LMP2A (Fig.amount of BZLF1 expression even without BCR cross-
1) would be phosphorylated, resulting in the binding oflinking (Fig. 6, lane 9), but the level of BZLF1 did not
the Syk PTK to LMP2A. Once bound, Syk would no longerincrease following BCR cross-linking as observed in the
be able to participate in normal BCR signal transduction.LMP2A ITAM mutants (Fig. 6, lanes 9 and 10). These
LMP2A might also desensitize or sequester other SH2-data demonstrate that both the Y74 and the Y85 residues
containing proteins through the interaction of their SH2of the LMP2A ITAM play an important role in the LMP2A-
domains with LMP2A phosphotyrosines. Recent studiesmediated inhibition of nuclear gene transcription follow-
have determined the optimal phosphopeptide motif foring BCR cross-linking and that the loss of either LMP2A
binding a particular SH2 domain (Songyang et al., 1993,ITAM tyrosine residue results in the induction of BZLF1
expression. 1994). LMP2A phosphotyrosine motifs similar to these
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identified motifs include potential binding sites for PI-3 vated resting B-cell phenotype in EBV-infected lympho-
cytes in normal individuals.kinase, PLCg2, Vav, Csk, and Lyn. Upon interaction with
We have shown that in in vitro systems, LMP2A dra-LMP2A, the functional activity of these proteins may be
matically alters the phenotype of B lymphocytes by down-altered.
modulating signal transduction in LCLs expressingThe importance of the Src family PTKs and the Syk
LMP2A (Miller et al., 1994, 1995). Two roles for LMP2APTK in BCR signal transduction and B-cell development
in latent EBV infection may be hypothesized; both arehas been demonstrated by homologous gene knock-outs
related to the ability of LMP2A to block normal BCR signalof either PTK in both murine and chicken model systems
transduction. The first role may be one in which LMP2A(Cheng et al., 1995; Hibbs et al., 1995; Nishizumi et al.,
alters the normal B-cell developmental program. This1995; Turner et al., 1995). The knock-out of Lyn from
may occur in the bone marrow, which may serve as onechicken B cells, the only Src family PTK expressed in
site of EBV latency in the human host (Gratama et al.,chicken B cells, results in a severe decrease in BCR
1989, 1992). In mice knocked out for the Syk PTK, normalsignaling, whereas the knock-out of Syk from chicken
B-cell development is arrested prior to the B lymphocytesB cells results in total loss of competent BCR signal
becoming BCR-positive in the bone marrow (Cheng ettransduction (Takata et al., 1994). These data position
al., 1995; Turner et al., 1995). If LMP2A has a similarSyk as the central mediator of BCR-mediated signal
effect on the Syk PTK in immature B lymphocytes in thetransduction. Interestingly, the absence of normal BCR
bone marrow as it does in BCR-positive B lymphocytes,signal transduction in EBV/LMP2A/ LCLs is very similar
LMP2A may arrest normal B-cell development, allowingto the Syk PTK knock-out in chicken B cells.
EBV to occupy a privileged site in the bone marrow. TheBy mutating the ITAM of LMP2A and demonstrating
second possible role of LMP2A in EBV latent infectionthe loss of LMP2A function, we have positioned the
may be to block normal BCR signal transduction in orderLMP2A ITAM and its effect on the Syk PTK as being
to prevent activation of lytic EBV replication induced bycentral in the ability of LMP2A to block BCR signal trans-
BCR signal transduction in peripheral B lymphocytes. Theduction. Mutational analyses of ITAM sequences within
importance of this function would be to prevent lytic repli-various lymphocyte receptors have indicated that both
cation in latently infected B lymphocytes as they circulatetyrosines of the ITAM are essential for both BCR and
in the peripheral blood, bone marrow, or lymphatic tis-
TCR signal transduction [for review see Bolen (1993);
sues where they might encounter antigens, superanti-
Cambier et al. (1994); Weiss and Littman (1994); De-
gens, or other ligands that could engage B-cell receptors
Franco (1995); Gold and Matsuuchi (1995)]. Changing
and activate EBV lytic replication. Transgenic animal
either of the conserved tyrosines in the CD3e, TCR z
model systems in which LMP2A is expressed in the B-
chain, Ig-a, or Ig-b ITAM to a phenylalanine residue cell compartment may begin to address these issues.
blocks normal signaling of chimeric proteins containing Further understanding of EBV latency in B lymphocytes
these domains (Romeo et al., 1992; Irving et al., 1993; might suggest novel treatments and therapeutics for
Flaswinkel and Reth, 1994). In addition, Zap-70 and Syk EBV-related diseases in humans.
PTK binding to ITAM peptides requires phosphorylation
of both ITAM tyrosines for maximum binding (Wange et
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